Zdravljenje pljučnega raka je odvisno od več dejavnikov, vključno s stopnjo raka, vrsto pljučnega raka in splošnim zdravstvenim stanjem bolnika.
Nekatere pogoste možnosti zdravljenja vključujejo:
1. Kirurški poseg: To je pogosto prednostno zdravljenje za rak pljuč v zgodnjem stadiju.
Kirurg odstrani tumor in majhen del zdravega tkiva okrog njega.
2. Radioterapija: Visokoenergetsko sevanje se uporablja za uničenje rakavih celic in krčenje tumorjev.
Uporablja se lahko samostojno ali v kombinaciji z drugimi zdravljenji.
3. Kemoterapija: Pri tem zdravljenju se uporabljajo zdravila, ki uničujejo rakave celice.
Lahko se daje intravensko ali peroralno in se pogosto uporablja v kombinaciji z drugimi zdravljenji.
4. Ciljno usmerjeno zdravljenje: To zdravljenje cilja na določene gene ali beljakovine, ki prispevajo k rasti in preživetju rakavih celic.
Pogosto se uporablja za napredovalni ali metastatski rak pljuč.
5. Imunoterapija: To zdravljenje pomaga imunski sistem prepoznati in napadati rakave celice.
Pogosto se uporablja za napredovalni ali metastatski rak pljuč.
6. Fotodinamična terapija: Pri tem zdravljenju se za uničenje rakavih celic uporablja zdravilo, ki se aktivira s svetlobo.
Pogosto se uporablja za rak pljuč v zgodnji fazi.
7. Protonska terapija: To je vrsta radioterapije, ki uporablja protone namesto rentgenskih žarkov za pošiljanje sevanja v tumor.
Pogosto se uporablja za rak pljuč v zgodnji fazi.
8. Klinična preskušanja: Bolniki so lahko upravičeni do sodelovanja v kliničnih preskušanjih, v katerih se preizkušajo nova zdravljenja ali kombinacije zdravljenj.
Pomembno je, da se o najboljših možnostih zdravljenja pogovorite z zdravstveno ekipo, saj bo najučinkovitejši načrt zdravljenja odvisen od posebne situacije posameznika.
Chen JH, Wu J, Xu Q: The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. , 4 (): 61.
Furuse K: [Photodynamic therapy of centrally located early-stage lung cancer]. Gan To Kagaku Ryoho. 1996, 23 (1): 27-30.
Gálffy G: [From rare mutations to classical ones, inhibition of signaling pathways in non-small cell lung cancer]. Magy Onkol. 2020, 64 (3): 196-204.
Magalhães M, Alvarez-Lorenzo C, Concheiro A, Figueiras A, Santos AC, Veiga F: RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers. Expert Opin Drug Deliv. 2018, 15 (10): 965-982.
Kataoka M, Fujiwara T, Tanaka N: [Gene therapy for lung cancer]. Nihon Geka Gakkai Zasshi. 2002, 103 (2): 244-9.
Jin C, Yang B: A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient. Case Rep Oncol. , 14 (1): 659-663.
Wang Y, Liu Q, Chen H, You J, Peng B, Cao F, Zhang X, Chen Q, Uzan G, Xu L, Zhang D: Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance. Anticancer Drugs. 2018, 29 (8): 748-755.
Opozorilo: medicinsko
Ta spletna stran je namenjena samo izobraževalnim in informacijskim namenom in ne pomeni zagotavljanja zdravniških nasvetov ali strokovnih storitev.
Posredovani podatki se ne smejo uporabljati za diagnozo ali zdravljenje zdravstvenega problema ali bolezni, tisti, ki iščejo osebni zdravniški nasvet, pa se morajo posvetovati z licenciranim zdravnikom.
Upoštevajte, da je nevronska mreža, ki ustvarja odgovore na vprašanja, še posebej netočna, ko gre za številčno vsebino, na primer število ljudi, diagnosticiranih z določeno boleznijo.
Vedno poiščite nasvet svojega zdravnika ali drugega usposobljenega zdravstvenega delavca glede zdravstvenega stanja. Nikoli ne prezrite strokovnega zdravniškega nasveta ali odložite iskanja zaradi nečesa, kar ste prebrali na tej spletni strani. Če menite, da imate zdravniški nujen primer, pokličite 911 ali takoj pojdite v najbližjo urgenco. Ta spletna stran ali njena uporaba ne ustvarja nobenega odnosa med zdravnikom in bolnikom. Niti BioMedLib niti njeni zaposleni, niti kateri koli sodelavec na tej spletni strani ne daje nobenih izjav, izrecnih ali implicitnih, v zvezi z informacijami, ki so na voljo na tej spletni strani ali z njeno uporabo.
Opozorilo: avtorske pravice
Zakon o avtorskih pravicah za digitalno tisočletje iz leta 1998, 17 U.S.C. § 512 (DMCA) zagotavlja sredstva za lastnike avtorskih pravic, ki menijo, da material, ki se pojavlja na internetu, krši njihove pravice v skladu z ameriškim zakonom o avtorskih pravicah.
Če v dobri veri menite, da katera koli vsebina ali material, ki je na voljo v povezavi z našo spletno stranjo ali storitvami, krši vaše avtorske pravice, nam lahko (ali vašemu zastopniku) pošljete obvestilo, v katerem zahtevate odstranitev vsebine ali materiala ali blokiranje dostopa do njega.
Obvestila je treba poslati v pisni obliki po e-pošti (za e-poštni naslov glejte razdelek "Kontakt").
DMCA zahteva, da vaše obvestilo o domnevni kršitvi avtorskih pravic vključuje naslednje informacije: (1) opis avtorsko varovanega dela, ki je predmet domnevne kršitve; (2) opis domnevne vsebine, ki krši avtorske pravice, in informacije, ki so zadostne, da nam omogočijo iskanje vsebine; (3) kontaktne informacije za vas, vključno z vašim naslovom, telefonsko številko in e-poštnim naslovom; (4) izjavo, da imate v dobri veri prepričanje, da vsebina na način, o katerem se pritožujete, ni odobrena s strani imetnika avtorskih pravic ali njegovega zastopnika ali z delovanjem katerega koli zakona;
(5) vašo izjavo, podpisano pod kaznijo krivokletstva, da so informacije v uradnem obvestilu točne in da imate pooblastilo za uveljavljanje avtorskih pravic, ki naj bi bile kršene;
in (6) fizični ali elektronski podpis imetnika avtorskih pravic ali osebe, pooblaščene, da deluje v imenu imetnika avtorskih pravic.
Če ne vključite vseh zgornjih informacij, se lahko obravnava vaše pritožbe odloži.
Kontaktni podatki
Prosimo, pošljite nam e-pošto s kakršnim koli vprašanjem / predlogom.
How to treat lung cancer?
The treatment for lung cancer depends on several factors, including the stage of the cancer, the type of lung cancer, and the patient's overall health.
Some common treatment options include:
1. Surgery: This is often the preferred treatment for early-stage lung cancer.
The surgeon removes the tumor and a small portion of healthy tissue around it.
2. Radiation therapy: High-energy radiation is used to kill cancer cells and shrink tumors.
It can be used alone or in combination with other treatments.
3. Chemotherapy: This treatment uses drugs to kill cancer cells.
It can be given intravenously or or orally, and is often used in combination with other treatments.
4. Targeted therapy: This treatment targets specific genes or proteins that contribute to the growth and survival of cancer cells.
It is often used for advanced or metastatic lung cancer.
5. Immunotherapy: This treatment helps the immune system recognize and attack cancer cells.
It is often used for advanced or metastatic lung cancer.
6. Photodynamic therapy: This treatment uses a light-activated drug to kill cancer cells.
It is often used for early-stage lung cancer.
7. Proton therapy: This is a type of radiation therapy that uses protons instead of x-rays to deliver radiation to the tumor.
It is often used for early-stage lung cancer.
8. Clinical trials: Patients may be eligible to participate in clinical trials testing new treatments or combinations of treatments.
It is important to discuss the best treatment options with a healthcare team, as the most effective treatment plan will depend on the individual's specific situation.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Približno
BioMedLib uporablja avtomatizirane računalnike (algoritme strojnega učenja) za ustvarjanje parov vprašanj in odgovorov.
Začeli smo s 35 milijoni biomedicinskih publikacij PubMed/Medline in spletnih strani RefinedWeb.
